ClinicalTrials.gg
CompletedNCT03867084Updated Apr 24, 2026Results posted

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

A Phase 3 interventional study of Pembrolizumab and Placebo in Hepatocellular Carcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 249 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
959
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing pembrolizumab in Carcinoma, Hepatocellular — 10 open to participants now, 12 under way, 1 of them phase 3. pembrolizumab · Carcinoma, Hepatocellular.

Enrollment
Largest of 36
959 · median 54
Started
2019
with 3 others
Phase 3
7 of 36
none open now
Registered
17th of 36
by date
Lead sponsor
6 of 36
Merck Sharp & Dohme LLC

Among the 36 studies testing pembrolizumab in Carcinoma, Hepatocellular, this one has the largest enrollment, is one of 4 that started in 2019, is one of 7 in phase 3, and was the 17th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

10 of the 36 studies testing pembrolizumab in Carcinoma, Hepatocellular are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing pembrolizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1) recurrence-free survival (RFS) as assessed by blinded independent central review (BICR); and 2) overall survival (OS).

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Programmed Cell Death 1 (PD-1, PD1)
  • Programmed Cell Death Ligand 1 (PD-L1, PDL1)
  • Checkpoint Inhibitor
  • Immunotherapy
  • Adjuvant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of HCC by radiological criteria and/or pathological confirmation.
  • Has an eligibility scan (CT of the chest, triphasic CT scan or MRI of the abdomen, and CT or MRI of the pelvis) confirming complete radiological response ≥4 weeks after complete surgical resection or local ablation. Randomization needs to occur within 12 weeks of the date of surgical resection or local ablation.
  • Has no radiologic evidence of disease prior to enrollment.
  • Has an (ECOG) performance status of 0 or 1 within 7 days prior to Cycle 1, Day 1.
  • Has a class A liver score (5 to 6 points) within 7 days prior to Cycle 1, Day 1.
  • Has alpha fetoprotein (AFP) concentration lower than 400 ng/mL within 28 days prior to Cycle 1, Day 1.
  • Has controlled (Hep B).
  • Has recovered adequately from toxicity and/or complications from the local intervention (surgical resection or local ablation) prior to starting study treatment.
  • If female, is not pregnant or breastfeeding, and at least one of the following conditions applies: 1) Is not a woman of (WOCBP); or 2) Is a WOCBP and using a method that is highly effective or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (a WOCBP must have a negative pregnancy test within 72 hours before the first dose of study treatment).
  • If undergoing surgical resection, has submitted a tumor tissue sample during Screening.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has a known additional that is progressing or has required active antineoplastic treatment (including hormonal) or surgery within the past 3 years.
  • Has had esophageal or gastric variceal bleeding within the last 6 months.
  • Has clinically apparent ascites on physical examination.
  • Has had clinically diagnosed hepatic encephalopathy in the last 6 months.
  • Has received local therapy to liver ablation other than with radiofrequency or microwave ablation.
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required or has current pneumonitis/interstitial lung disease.
  • Has an active infection requiring systemic therapy.
  • Has dual active Virus (HBV) and Virus (HCV) infection at study entry.
  • Has a known history of (HIV) infection.
  • Has known active tuberculosis (TB; Bacillus tuberculosis).
  • Has received prior therapy with an , anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
  • Has received prior systemic anti-cancer therapy for HCC including agents.
  • Is receiving any of the following prohibited concomitant therapies:1) Antineoplastic systemic chemotherapy or biological therapy; 2) Immunotherapy not specified in this protocol; 3) Investigational agents other than pembrolizumab; 4) Radiation therapy; 5) Oncological surgical therapy; or systemic glucocorticoids for any purpose other than to modulate symptoms from an AE that is suspected to have an immunologic etiology.
  • Has received a within 30 days prior to the first dose of study treatment.
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to Cycle 1, Day 1.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of therapy within 7 days prior to Cycle 1, Day 1.
  • Has severe (≥Grade 3) to pembrolizumab and/or any of its .
  • Has an active disease that has required systemic treatment in past 2 years.
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  • Has had an allogenic tissue/solid organ transplant.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
959 participants (actual)

Study arms

  • Experimental
    Pembrolizumab

    Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle for up to 17 cycles.

    Biological: Pembrolizumab

  • Placebo comparator
    Placebo

    Participants receive IV placebo on Day 1 of each 21-day cycle for up to 17 cycles.

    Drug: Placebo

Interventions

  • BiologicalPembrolizumab

    IV infusion of Pembrolizumab 200 mg.

    Also known as: KEYTRUDA®, MK-3475

  • DrugPlacebo

    IV infusion of 0.9% normal saline.

06

What researchers measure

Primary outcomes

  1. Recurrence-Free Survival (RFS)

    RFS was defined as the time from randomization to first documentation of disease recurrence (local, regional, or distant) as assessed by blinded independent central review (BICR) or by pathology consistent with HCC if required per the site's standard of care, or death due to any cause (both cancer and non-cancer causes of death), whichever occurred first. RFS was reported for each arm.

    Time frame: Up to approximately 69 months

  2. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. OS was reported for each arm.

    Time frame: Up to approximately 69 months

Secondary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy was determined. The number of participants who experienced an AE were reported.

    Time frame: Up to approximately 26 months

  2. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy was determined. The number of participants who discontinued study treatment due to an AE were reported.

    Time frame: Up to approximately 23 months

  3. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status (GHS) / Quality of Life (QoL) Scale Score

    The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participants responded to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicated a better outcome. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score was reported.

    Time frame: Baseline and up to approximately 120 weeks

  4. Change From Baseline in EORTC QLQ-C30 Physical Functioning Scale Score

    The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. Participants responded to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated better physical functioning. The change from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) combined score was reported.

    Time frame: Baseline and up to approximately 120 weeks

  5. Change From Baseline in EORTC QLQ-C30 Role Functioning Scale Score

    The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score was reported.

    Time frame: Baseline and up to approximately 120 weeks

  6. Change From Baseline in EORTC QLQ-Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Abdominal Swelling Scale Score

    The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The abdominal swelling scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores were standardized, so that scores range from 0-100. Higher scores indicated more severe symptoms/problems. Change from baseline in the EORTC QLQ-HCC18 abdominal swelling scale score was reported.

    Time frame: Baseline and up to approximately 120 weeks

  7. Change From Baseline in EORTC QLQ-HCC18 Fatigue Scale Score

    The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The fatigue scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated more severe symptoms/problems. Change from baseline in the EORTC QLQ-HCC18 fatigue scale score was reported.

    Time frame: Baseline and up to approximately 120 weeks

  8. Change From Baseline in EORTC QLQ-HCC18 Pain Scale Score

    The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The pain scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated more severe symptoms/problems. Change from baseline in the EORTC QLQ-HCC18 pain scale score was reported.

    Time frame: Baseline and up to approximately 120 weeks

  9. Change From Baseline in Visual Analogue Scale (VAS) Score on the European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Health Utility Score

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The VAS is a component of the EQ-5D-5L that asked participants to rate their overall health on a vertical visual analogue scale, with the scale's ends labelled 'The best health you can imagine' (equivalent to a score of 0) and 'The worst health you can imagine' (equivalent to a score of 100).

    Time frame: Baseline and up to approximately 120 weeks

  10. Time to Deterioration (TTD) in the EORTC QLQ-C30 Combined GHS / QoL Scale Score

    EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participants responded to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicated a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicated a better outcome.

    Time frame: Baseline and up to approximately 120 weeks

  11. TTD in the EORTC QLQ-C30 Physical Functioning Scale Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participants responded to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicated a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicated a better outcome.

    Time frame: Baseline and up to approximately 120 weeks

  12. TTD in the EORTC QLQ-C30 Role Functioning Scale Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participants responded to questions about their role functioning (Items 6 and 7) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of Items 6 and 7 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicated a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 6 and 7). A longer TTD indicated a better outcome.

    Time frame: Baseline and up to approximately 120 weeks

  13. TTD in the EORTC QLQ-HCC18 Abdominal Swelling Scale Score

    The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The abdominal swelling scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores were standardized, so that scores range from 0-100. Higher scores indicated more severe symptoms/problems. The TTD in EORTC QLQ-HCC18 abdominal swelling scale score was reported, defined as the time to first onset of a ≥10 point decrease from baseline.

    Time frame: Baseline and up to approximately 120 weeks

  14. TTD in the EORTC QLQ-HCC18 Fatigue Scale Score

    The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The fatigue scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated more severe symptoms/problems. The TTD in EORTC QLQ-HCC18 fatigue scale score was reported, defined as the time to first onset of a ≥10 point decrease from baseline.

    Time frame: Baseline and up to approximately 120 weeks

  15. TTD in the EORTC QLQ-HCC18 Pain Scale Score

    The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The pain scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated more severe symptoms/problems. The TTD in EORTC QLQ-HCC18 pain scale score was reported, defined as the time to first onset of a ≥10 point decrease from baseline.

    Time frame: Baseline and up to approximately 120 weeks

07

Results

Posted Apr 24, 2026

Participant flow

Participants at least 18 years of age with hepatocellular carcinoma (HCC) and who had complete radiological response after surgical resection or local ablation were recruited.

Participant flow — Overall Study
MilestonePembrolizumabPlacebo
Started476483
Treated471482
Completed00
Not completed476483
Withdrew: Death107109
Withdrew: Lost to follow-up33
Withdrew: Physician decision3017
Withdrew: Randomized by mistake without study treatment10
Withdrew: Sponsor decision305334
Withdrew: Withdrawal by subject3020

Outcome measures

SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy was determined. The number of participants who experienced an AE were reported.

Time frame:
Up to approximately 26 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPembrolizumabPlacebo
Number of Participants Who Experienced an Adverse Event (AE)430397
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy was determined. The number of participants who discontinued study treatment due to an AE were reported.

Time frame:
Up to approximately 23 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsPembrolizumabPlacebo
Number of Participants Who Discontinued Study Treatment Due to an AE5817
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status (GHS) / Quality of Life (QoL) Scale Score

The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participants responded to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicated a better outcome. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score was reported.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status (GHS) / Quality of Life (QoL) Scale Score
Score on a ScalePembrolizumabPlacebo
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status (GHS) / Quality of Life (QoL) Scale Score-3.48 (-5.24 to -1.73)-2.13 (-3.89 to -0.36)
Statistical analysis
  • Pembrolizumab vs Placebo · cLDA model · p = 0.2563 (Two-sided nominal p-value based on a cLDA model stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Mean difference (final values): -1.36 · 95% CI -3.70 to 0.99
SecondaryChange From Baseline in EORTC QLQ-C30 Physical Functioning Scale Score

The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. Participants responded to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated better physical functioning. The change from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) combined score was reported.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in EORTC QLQ-C30 Physical Functioning Scale Score
Score on a ScalePembrolizumabPlacebo
Change From Baseline in EORTC QLQ-C30 Physical Functioning Scale Score-1.98 (-3.46 to -0.5)-1.74 (-3.23 to -0.25)
Statistical analysis
  • Pembrolizumab vs Placebo · cLDA model · p = 0.8165 (Two-sided nominal p-value based on a cLDA model stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Mean difference (final values): -0.24 · 95% CI -2.28 to 1.80
SecondaryChange From Baseline in EORTC QLQ-C30 Role Functioning Scale Score

The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score was reported.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in EORTC QLQ-C30 Role Functioning Scale Score
Score on a ScalePembrolizumabPlacebo
Change From Baseline in EORTC QLQ-C30 Role Functioning Scale Score-1.93 (-3.94 to 0.07)-1.71 (-3.73 to 0.30)
Statistical analysis
  • Pembrolizumab vs Placebo · cLDA model · p = 0.8714 (Two-sided nominal p-value based on a cLDA model stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Mean difference (final values): -0.22 · 95% CI -2.89 to 2.45
SecondaryChange From Baseline in EORTC QLQ-Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Abdominal Swelling Scale Score

The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The abdominal swelling scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores were standardized, so that scores range from 0-100. Higher scores indicated more severe symptoms/problems. Change from baseline in the EORTC QLQ-HCC18 abdominal swelling scale score was reported.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in EORTC QLQ-Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Abdominal Swelling Scale Score
Score on a ScalePembrolizumabPlacebo
Change From Baseline in EORTC QLQ-Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Abdominal Swelling Scale Score2.20 (0.23 to 4.16)0.86 (-1.12 to 2.84)
Statistical analysis
  • Pembrolizumab vs Placebo · cLDA model · p = 0.3091 (Two-sided nominal p-value based on a cLDA model stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Mean difference (final values): 1.34 · 95% CI -1.24 to 3.92
SecondaryChange From Baseline in EORTC QLQ-HCC18 Fatigue Scale Score

The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The fatigue scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated more severe symptoms/problems. Change from baseline in the EORTC QLQ-HCC18 fatigue scale score was reported.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in EORTC QLQ-HCC18 Fatigue Scale Score
Score on a ScalePembrolizumabPlacebo
Change From Baseline in EORTC QLQ-HCC18 Fatigue Scale Score1.63 (-0.19 to 3.46)0.96 (-0.88 to 2.80)
Statistical analysis
  • Pembrolizumab vs Placebo · cLDA model · p = 0.5913 (Two-sided nominal p-value based on a cLDA model stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Mean difference (final values): 0.67 · 95% CI -1.79 to 3.14
SecondaryChange From Baseline in EORTC QLQ-HCC18 Pain Scale Score

The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The pain scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated more severe symptoms/problems. Change from baseline in the EORTC QLQ-HCC18 pain scale score was reported.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in EORTC QLQ-HCC18 Pain Scale Score
Score on a ScalePembrolizumabPlacebo
Change From Baseline in EORTC QLQ-HCC18 Pain Scale Score2.33 (0.72 to 3.93)1.03 (-0.59 to 2.65)
Statistical analysis
  • Pembrolizumab vs Placebo · cLDA model · p = 0.2318 (Two-sided nominal p-value based on a cLDA model stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Mean difference (final values): 1.29 · 95% CI -0.83 to 3.42
SecondaryChange From Baseline in Visual Analogue Scale (VAS) Score on the European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Health Utility Score

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. The VAS is a component of the EQ-5D-5L that asked participants to rate their overall health on a vertical visual analogue scale, with the scale's ends labelled 'The best health you can imagine' (equivalent to a score of 0) and 'The worst health you can imagine' (equivalent to a score of 100).

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Visual Analogue Scale (VAS) Score on the European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Health Utility Score
Score on a ScalePembrolizumabPlacebo
Change From Baseline in Visual Analogue Scale (VAS) Score on the European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Health Utility Score-3.54 (-4.96 to -2.12)-2.10 (-3.53 to -0.68)
Statistical analysis
  • Pembrolizumab vs Placebo · cLDA model · p = 0.1356 (Two-sided nominal p-value based on a cLDA model stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Mean difference (final values): -1.43 · 95% CI -3.32 to 0.45
SecondaryTime to Deterioration (TTD) in the EORTC QLQ-C30 Combined GHS / QoL Scale Score

EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participants responded to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicated a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicated a better outcome.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Median · Months
Time to Deterioration (TTD) in the EORTC QLQ-C30 Combined GHS / QoL Scale Score
MonthsPembrolizumabPlacebo
Time to Deterioration (TTD) in the EORTC QLQ-C30 Combined GHS / QoL Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab vs Placebo · Log Rank · p = 0.2905 (Two-sided nominal p-value based on log-rank test stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Hazard ratio (hr): 1.13 · 95% CI 0.90 to 1.40
SecondaryTTD in the EORTC QLQ-C30 Physical Functioning Scale Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participants responded to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicated a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicated a better outcome.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Median · Months
TTD in the EORTC QLQ-C30 Physical Functioning Scale Score
MonthsPembrolizumabPlacebo
TTD in the EORTC QLQ-C30 Physical Functioning Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab vs Placebo · Log Rank · p = 0.5948 (Two-sided nominal p-value based on log-rank test stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Hazard ratio (hr): 1.07 · 95% CI 0.83 to 1.39
SecondaryTTD in the EORTC QLQ-C30 Role Functioning Scale Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participants responded to questions about their role functioning (Items 6 and 7) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of Items 6 and 7 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicated a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 6 and 7). A longer TTD indicated a better outcome.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Median · Months
TTD in the EORTC QLQ-C30 Role Functioning Scale Score
MonthsPembrolizumabPlacebo
TTD in the EORTC QLQ-C30 Role Functioning Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab vs Placebo · Log Rank · p = 0.1906 (Two-sided nominal p-value based on log-rank test stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Hazard ratio (hr): 1.18 · 95% CI 0.92 to 1.50
SecondaryTTD in the EORTC QLQ-HCC18 Abdominal Swelling Scale Score

The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The abdominal swelling scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores were standardized, so that scores range from 0-100. Higher scores indicated more severe symptoms/problems. The TTD in EORTC QLQ-HCC18 abdominal swelling scale score was reported, defined as the time to first onset of a ≥10 point decrease from baseline.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Median · Months
TTD in the EORTC QLQ-HCC18 Abdominal Swelling Scale Score
MonthsPembrolizumabPlacebo
TTD in the EORTC QLQ-HCC18 Abdominal Swelling Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab vs Placebo · Log Rank · p = 0.8449 (Two-sided nominal p-value based on log-rank test stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Hazard ratio (hr): 1.03 · 95% CI 0.78 to 1.36
SecondaryTTD in the EORTC QLQ-HCC18 Fatigue Scale Score

The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The fatigue scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated more severe symptoms/problems. The TTD in EORTC QLQ-HCC18 fatigue scale score was reported, defined as the time to first onset of a ≥10 point decrease from baseline.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Median · Months
TTD in the EORTC QLQ-HCC18 Fatigue Scale Score
MonthsPembrolizumabPlacebo
TTD in the EORTC QLQ-HCC18 Fatigue Scale ScoreNA (33.15 to NA)NA (38.64 to NA)
Statistical analysis
  • Pembrolizumab vs Placebo · Log Rank · p = 0.7812 (Two-sided nominal p-value based on log-rank test stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Hazard ratio (hr): 1.03 · 95% CI 0.84 to 1.26
SecondaryTTD in the EORTC QLQ-HCC18 Pain Scale Score

The EORTC QLQ-HCC18 is an HCC-specific questionnaire, administered in addition to the EORTC QLQ-C30. The pain scale score was based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicated more severe symptoms/problems. The TTD in EORTC QLQ-HCC18 pain scale score was reported, defined as the time to first onset of a ≥10 point decrease from baseline.

Time frame:
Baseline and up to approximately 120 weeks
Reported as:
Median · Months
TTD in the EORTC QLQ-HCC18 Pain Scale Score
MonthsPembrolizumabPlacebo
TTD in the EORTC QLQ-HCC18 Pain Scale ScoreNA (44.19 to NA)NA (50.04 to NA)
Statistical analysis
  • Pembrolizumab vs Placebo · Log Rank · p = 0.9982 (Two-sided nominal p-value based on log-rank test stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Hazard ratio (hr): 1.00 · 95% CI 0.81 to 1.23
PrimaryRecurrence-Free Survival (RFS)

RFS was defined as the time from randomization to first documentation of disease recurrence (local, regional, or distant) as assessed by blinded independent central review (BICR) or by pathology consistent with HCC if required per the site's standard of care, or death due to any cause (both cancer and non-cancer causes of death), whichever occurred first. RFS was reported for each arm.

Time frame:
Up to approximately 69 months
Reported as:
Median · Months
Recurrence-Free Survival (RFS)
MonthsPembrolizumabPlacebo
Recurrence-Free Survival (RFS)46.7 (35.6 to 53.3)45.5 (35.6 to 58.0)
Statistical analysis
  • Pembrolizumab vs Placebo · Log Rank · p = 0.7190 (One-sided p-value based on log-rank test stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Hazard ratio (hr): 1.06 · 95% CI 0.88 to 1.26
PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. OS was reported for each arm.

Time frame:
Up to approximately 69 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumabPlacebo
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab vs Placebo · Log Rank · p = 0.7043 (One-sided nominal p-value based on log-rank test stratified by geographic region, prior local therapy, risk of recurrence, and AFP with small strata collapsed.) · Hazard ratio (hr): 1.08 · 95% CI 0.81 to 1.43

Adverse events

Collected over Up to approximately 74 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab109/476 (22.9%)103/471 (21.9%)350/471 (74.3%)
Placebo109/483 (22.6%)59/482 (12.2%)278/482 (57.7%)
Most frequent serious events
Showing 10 of 158
Most frequent serious events
EventPembrolizumabPlacebo
Immune-mediated hepatitisHepatobiliary disorders8/4710/482
Adrenal insufficiencyEndocrine disorders5/4710/482
PneumoniaInfections and infestations5/4711/482
ColitisGastrointestinal disorders4/4710/482
PneumonitisRespiratory, thoracic and mediastinal disorders4/4710/482
PyrexiaGeneral disorders3/4711/482
Cholecystitis acuteHepatobiliary disorders3/4710/482
HyponatraemiaMetabolism and nutrition disorders3/4710/482
Inguinal herniaGastrointestinal disorders0/4713/482
Myocardial infarctionCardiac disorders2/4711/482
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPembrolizumabPlacebo
PruritusSkin and subcutaneous tissue disorders94/47141/482
RashSkin and subcutaneous tissue disorders60/47126/482
DiarrhoeaGastrointestinal disorders53/47141/482
ArthralgiaMusculoskeletal and connective tissue disorders51/47142/482
HypothyroidismEndocrine disorders47/4719/482
FatigueGeneral disorders46/47146/482
Aspartate aminotransferase increasedInvestigations46/47132/482
Alanine aminotransferase increasedInvestigations39/47129/482
Back painMusculoskeletal and connective tissue disorders37/47130/482
Platelet count decreasedInvestigations36/47131/482

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PembrolizumabPlaceboTotal
Mean61.4 ± 10.761.0 ± 11.561.2 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)PembrolizumabPlaceboTotal
Female10199200
Male375384759
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PembrolizumabPlaceboTotal
Hispanic or Latino131427
Not Hispanic or Latino436455891
Unknown or Not Reported271441
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PembrolizumabPlaceboTotal
American Indian or Alaska Native000
Asian268262530
Native Hawaiian or Other Pacific Islander235
Black or African American6410
White196212408
More than one race101
Unknown or Not Reported325
Prior Local Therapy
Prior Local Therapy(Participants)PembrolizumabPlaceboTotal
Resection421424845
Ablation5559114
Recurrence Risk Group
Recurrence Risk Group(Participants)PembrolizumabPlaceboTotal
Intermediate96103199
High350343693
Very High303767
Alpha Fetoprotein (AFP) at Initial Diagnosis Prior to Resection or Ablation
Alpha Fetoprotein (AFP) at Initial Diagnosis Prior to Resection or Ablation(Participants)PembrolizumabPlaceboTotal
>=200 ng/mL9197188
<200 ng/mL368374742
Missing171229
Region of Enrolling Site
Region of Enrolling Site(Participants)PembrolizumabPlaceboTotal
Asia without Japan207197404
Non-Asia and Japan269286555
08

Study locations

249 sites
  • Banner MD Anderson Cancer Center ( Site 0026)
    Gilbert, Arizona 85234, United States
  • The University of Arizona Cancer Center - North Campus ( Site 0039)
    Tucson, Arizona 85719, United States
  • City of Hope Medical Center ( Site 0027)
    Duarte, California 91010, United States
  • Smilow Cancer Hospital at Yale New Haven ( Site 0042)
    New Haven, Connecticut 06510, United States
  • Regional Cancer Center ( Site 0054)
    Fort Myers, Florida 33905, United States
  • Indiana University Simon Cancer Center ( Site 0075)
    Indianapolis, Indiana 46202, United States
  • University of Iowa ( Site 0067)
    Iowa City, Iowa 52242, United States
  • James Graham Brown Cancer Center ( Site 0088)
    Louisville, Kentucky 40202, United States
  • University of Louisville ( Site 0059)
    Louisville, Kentucky 40202, United States
  • University Medical Center New Orleans ( Site 0014)
    New Orleans, Louisiana 70112, United States
  • Massachusetts General Hospital ( Site 0062)
    Boston, Massachusetts 02114, United States
  • Boston Medical Center ( Site 0025)
    Boston, Massachusetts 02118, United States
  • Beth Israel Deaconess Medical Ctr. ( Site 0033)
    Boston, Massachusetts 02215, United States
  • University of Massachusetts Worcester ( Site 0017)
    Worcester, Massachusetts 01655, United States
  • Henry Ford Hospital-GI/Hepatology Research ( Site 0047)
    Detroit, Michigan 48202, United States
  • University of New Mexico ( Site 0041)
    Albuquerque, New Mexico 87131, United States
  • North Shore-Long Island Jewish Health System ( Site 0068)
    Lake Success, New York 11042, United States
  • Miami Valley Hospital South ( Site 0093)
    Centerville, Ohio 45459, United States
  • University of Cincinnati Medical Center ( Site 0084)
    Cincinnati, Ohio 45219, United States
  • ProMedica Flower Hospital ( Site 0090)
    Sylvania, Ohio 43560, United States
  • Stephenson Cancer Center ( Site 0045)
    Oklahoma City, Oklahoma 73104, United States
  • Vanderbilt Ingram Cancer Center ( Site 0006)
    Nashville, Tennessee 37232, United States
  • Baylor Scott & White Medical Center - Temple ( Site 0089)
    Temple, Texas 76508, United States
  • Virginia Mason Medical Center ( Site 0028)
    Seattle, Washington 98101, United States
  • Hospital Universitario Austral ( Site 0795)
    Pilar, Buenos Aires B1629AHJ, Argentina
  • Fundación favaloro para la Docencia e Investigación Médica ( Site 0808)
    Buenos Aires, Buenos Aires F.D. C1096AAS, Argentina
  • Hospital Provincial del Centenario ( Site 0794)
    Rosario, Santa Fe Province S2002KDS, Argentina
  • Hospital Aleman ( Site 0806)
    Buenos Aires, C1118AAT, Argentina
  • Hospital Italiano ( Site 0793)
    Buenos Aires, C1181ACH, Argentina
  • Hospital Britanico de Buenos Aires ( Site 0792)
    Buenos Aires, C1280AEB, Argentina
  • Clinica de nefrologia urologia y enfermedades cardiovasculares ( Site 0802)
    Santa Fe, S3000BPJ, Argentina
  • Royal Prince Alfred Hospital AW ( Site 0225)
    Camperdown, New South Wales 2050, Australia
  • Liverpool Hospital ( Site 0226)
    Liverpool, New South Wales 2170, Australia
  • Princess Alexandra Hospital ( Site 0228)
    Woollongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital ( Site 0234)
    Adelaide, South Australia 5000, Australia
  • Monash Health ( Site 0233)
    Clayton, Victoria 3168, Australia
  • St Vincents Hospital Melbourne ( Site 0227)
    Fitzroy, Victoria 3065, Australia
  • Alfred Health ( Site 0230)
    Melbourne, Victoria 3004, Australia
  • Royal Perth Hospital ( Site 0229)
    Perth, Western Australia 6000, Australia
  • University Hospital Antwerp (UZA) ( Site 0374)
    Edegem, Antwerpen 02650, Belgium
  • Erasme Hospital ( Site 0376)
    Brussels, Bruxelles-Capitale, Region de 1070, Belgium
  • UZ Gent ( Site 0375)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven ( Site 0377)
    Leuven, Vlaams-Brabant 3000, Belgium
  • CIONC - Centro Integrado de Oncologia de Curitiba ( Site 0813)
    Curitiba, Paraná 80810-050, Brazil
  • Hospital de Cancer de Pernambuco ( Site 0815)
    Recife, Pernambuco 50040-000, Brazil
  • Hospital de Clinicas de Porto Alegre ( Site 0824)
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Clinica de Oncologia Reichow ( Site 0818)
    Blumenau, Santa Catarina 89010-340, Brazil
  • Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0820)
    Itajaí, Santa Catarina 88301-220, Brazil
  • Hospital Paulistano ( Site 0829)
    São Paulo, São Paulo 01321-001, Brazil
  • Instituto COI de Pesquisa Educacao e Gestao ( Site 0825)
    Rio de Janeiro, 22793-080, Brazil
  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0826)
    São Paulo, 01246-000, Brazil
  • Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0828)
    São Paulo, 01321-001, Brazil
  • A.C. Camargo Cancer Center ( Site 0827)
    São Paulo, 01509-900, Brazil
  • Casa de Saude Santa Marcelina ( Site 0821)
    São Paulo, 08270120, Brazil
  • Complex Cancer Center Plovdiv-First Medical Oncology Department ( Site 0982)
    Plovdiv, 4004, Bulgaria
  • Nova Scotia Health Authority QEII-HSC ( Site 0208)
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0211)
    Montreal, Quebec H2X 3E4, Canada
  • McGill University Health Centre ( Site 0207)
    Montreal, Quebec H4A 3J1, Canada
  • Anhui Provincil Hospital South District ( Site 0181)
    Hefei, Anhui 230036, China
  • Cancer Hospital Chinese Academy of Medical Sciences ( Site 0156)
    Beijing, Beijing Municipality 100021, China
  • Peking University People's Hospital ( Site 0191)
    Beijing, Beijing Municipality 100044, China
  • Beijing Cancer Hospital ( Site 0155)
    Beijing, Beijing Municipality 100142, China
  • Fujian Provincial Cancer Hospital ( Site 0165)
    Fuzhou, Fujian 350014, China
  • 900 Hospital of the Joint ( Site 0197)
    Fuzhou, Fujian 350025, China
  • Guangdong General Hospital ( Site 0166)
    Guangzhou, Guangdong 510080, China
  • Southern Medical University Nanfang Hospital ( Site 0172)
    Guangzhou, Guangdong 510515, China
  • Wuhan Union Hospital ( Site 0173)
    Wuhan, Hubei 430022, China
  • Hubei Cancer Hospital ( Site 0189)
    Wuhan, Hubei 430079, China
  • The Third Xiangya Hospital of Central South University ( Site 0167)
    Changsha, Hunan 410000, China
  • Hunan Provincial People Hospital ( Site 0192)
    Changsha, Hunan 410005, China
  • Hunan Cancer Hospital ( Site 0168)
    Changsha, Hunan 410013, China
  • Fudan University Shanghai Cancer Center ( Site 0161)
    Shanghai, Shanghai Municipality 200032, China
  • Zhongshan Hospital Fudan University ( Site 0193)
    Shanghai, Shanghai Municipality 200032, China
  • Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0174)
    Shanghai, Shanghai Municipality 200127, China
  • Zhongshan Hospital affiliated to Fudan University ( Site 0153)
    Shanghai, Shanghai Municipality 210000, China
  • The First Affiliated Hospital of Xi an Jiaotong University ( Site 0164)
    Xi’an, Shanxi 710061, China
  • West China Hospital of Sichuan University ( Site 0162)
    Chengdu, Sichuan 610041, China
  • Affiliated Tumor Hospital of Xinjiang Medical University ( Site 0157)
    Ürümqi, Xinjiang 830001, China
  • Zhejiang Cancer Hospital ( Site 0171)
    Hangzhou, Zhejiang 310022, China
  • Herlev Hospital ( Site 0421)
    Herlev, Capital Region 2730, Denmark
  • Aarhus Universitets hospital ( Site 0420)
    Aarhus N, Central Jutland 8200, Denmark
  • Odense Universitets Hospital ( Site 0422)
    Odense C, Region Syddanmark 5000, Denmark
  • HUS Hopital Hautepierre ( Site 0445)
    Strasbourg, Bas-Rhin 67098, France
  • Hopital de la Timone ( Site 0442)
    Marseille, Bouches-du-Rhone 13005, France
  • CHU Bordeaux Haut-Leveque ( Site 0437)
    Pessac, Gironde 33604, France
  • CHU Rangueil ( Site 0441)
    Toulouse, Haute-Garonne 31059, France
  • Hopital Beaujon ( Site 0439)
    Clichy, Hauts-de-Seine 92118, France
  • CHU Montpellier. ( Site 0443)
    Montpellier, Herault 34295, France
  • Hopital Claude Huriez CHRU LILLE ( Site 0440)
    Lille, Nord 59037, France
  • Hopital Paul Brousse ( Site 0447)
    Villejuif, Val-de-Marne 94800, France
  • SLK-Kliniken Heilbronn GmbH ( Site 0460)
    Heilbronn, Baden-Wurttemberg 74078, Germany
  • Universitaetsklinikum Tuebingen ( Site 0466)
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Klinikum rechts der Isar der Technischen Universitaet ( Site 0470)
    Munich, Bavaria 81675, Germany
  • Universitaetsklinikum Wuerzburg ( Site 0468)
    Würzburg, Bavaria 97080, Germany
  • Krankenhaus Nord-West GmbH ( Site 0472)
    Frankfurt am Main, Hesse 60488, Germany
  • Universitaetsklinikum Frankfurt ( Site 0467)
    Frankfurt am Main, Hesse 60596, Germany
  • Medizinische Hochschule Hannover ( Site 0458)
    Hanover, Lower Saxony 30625, Germany
  • Universitaetsklinikum Koeln ( Site 0463)
    Cologne, North Rhine-Westphalia 50937, Germany
  • Universitaetsklinikum Duesseldorf ( Site 0461)
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Staedtisches Klinikum Dresden ( Site 0471)
    Dresden, Saxony 01067, Germany

Showing the first 100 of 249 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Verset G, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer DH, Vogel A, Edeline J, Cattan S, Kudo M, Cheng AL, Ogasawara S, Daniele B, Chan SL, Knox JJ, Qin S, Siegel AB, Chisamore M, Hatogai K, Wang A, Finn RS, Zhu AX. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clin Cancer Res. 2022 Jun 13;28(12):2547-2554. doi: 10.1158/1078-0432.CCR-21-3807. PubMed 35421228 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Mar 2025, 69 months.

Results were first posted in Apr 2026, 1 year 1 month after primary completion.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 69 months is above that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2019
First posted
Mar 7, 2019
StartActual
May 28, 2019
Primary completionActual
Mar 20, 2025
CompletionActual
Sep 30, 2025
Results first posted
Apr 24, 2026
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03867084
Responsible party
Sponsor
First posted
Mar 7, 2019
Start date
May 28, 2019
Primary completion
Mar 20, 2025
Completion
Sep 30, 2025
Results posted
Apr 24, 2026
Last update
Apr 24, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion